Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

BACKGROUND: Immune checkpoint inhibition has been shown to have limited efficacy in patients with metastatic prostate cancer. Prostate cancers that harbor certain homologous recombination (HR) DNA repair gene mutations, inactivating CDK12 mutations or have underlying mismatch repair deficiency may b...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Prostate
Autores principales: Markowski, Mark C., Shenderov, Eugene, Eisenberger, Mario A., Kachhap, Sushant, Pardoll, Drew M., Denmeade, Samuel R., Antonarakis, Emmanuel S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585736/
https://ncbi.nlm.nih.gov/pubmed/31972048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23955
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares